EMERGENT BIOSOLUTIONS INC. COMMON STOCK

Emergent BioSolutions Provides Corporate Governance Update

23 Mar 2022 15:05:00 By Nasdaq GlobeNewswire

Emergent BioSolutions to Participate in Investor Conferences

14 Mar 2022 15:05:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Initiates Phase 1 Study Evaluating Potential Intranasal Treatment for Cyanide Poisoning

11 Mar 2022 05:34:09 By Nasdaq GlobeNewswire

Emergent BioSolutions Reports Financial Results for Fourth Quarter 2021

24 Feb 2022 15:05:03 By Nasdaq GlobeNewswire

Emergent BioSolutions to Release Fourth Quarter 2021 Financial Results and Conduct Conference Call on February 24, 2022

07 Feb 2022 05:30:00 By Nasdaq GlobeNewswire

Founder and Executive Chairman of Emergent BioSolutions Announces Retirement

14 Jan 2022 05:30:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces 2022 Financial Guidance, Provides Preliminary 2021 Results

09 Jan 2022 13:00:00 By Nasdaq GlobeNewswire

Emergent BioSolutions to Participate in Investor Conferences

03 Jan 2022 05:30:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces Initiation of Phase 1 Study Evaluating Its Universal Influenza Vaccine Candidate

16 Dec 2021 06:30:29 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces Stock Repurchase Program

11 Nov 2021 15:05:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Reports Financial Results For Third Quarter 2021

04 Nov 2021 15:05:02 By Nasdaq GlobeNewswire

Emergent BioSolutions to Release Third Quarter 2021 Financial Results and Conduct a Conference Call on November 4, 2021

18 Oct 2021 05:30:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces Initiation of Pivotal Phase 3 Study Evaluating the Safety and Immunogenicity of Its Single-Dose Chikungunya Vaccine Candidate, CHIKV VLP

15 Oct 2021 05:30:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Secures Multi-Year Development and Manufacturing Agreement with Providence Therapeutics for its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B

14 Sep 2021 07:00:02 By Nasdaq GlobeNewswire

Emergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Evaluated in NIH-Sponsored Phase 3 Clinical Trial (INSIGHT-012) of Hyperimmune Intravenous Immunoglobulin for Outpatient Treatment of COVID-19

25 Aug 2021 05:30:00 By Nasdaq GlobeNewswire

Emergent BioSolutions to Participate in Investor Conferences

23 Aug 2021 15:05:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Reports Financial Results For Second Quarter 2021

29 Jul 2021 15:05:01 By Nasdaq GlobeNewswire

Emergent BioSolutions to Resume Manufacturing Covid-19 Vaccine at Bayview Facility

29 Jul 2021 06:24:59 By Nasdaq GlobeNewswire

Reverse the Silence Campaign Casts a National Spotlight on Overdose Risks Associated with Opioid Use

26 Jul 2021 08:01:00 By Nasdaq GlobeNewswire

Emergent BioSolutions to Release Second Quarter 2021 Financial Results and Conduct a Conference Call on July 29, 2021

15 Jul 2021 05:30:00 By Nasdaq GlobeNewswire